ACRV logo

ACRV Acrivon Therapeutics, Inc. Common Stock

NASDAQ Global Market · Biotechnology · Healthcare

$1.15
-0.25 (-17.86%)

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteo…

Market Cap: $49.35Mwww.acrivon.com

Price

No data yet.

Social Signal Score

54
5d
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
61
4 mentions
—
news: 4

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 1Sell 0Strong Sell 0
Avg price target$21.83+1798.3%
Low $17Median $20High $30
Current Consensus

Revenue

$0.00
$0.00
Sep 2021Sep 2026

Analyst Estimates

FY2025
$-2.03
$-2.06–$-2.00
6 analysts
FY2026
$-1.80
$-1.90–$-1.60
4 analysts
FY2027
$-1.52
$-2.23–$-0.90
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Peter Blume-Jensen
Sector
Healthcare
Industry
Biotechnology
Employees
75
Beta
1.93
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-5.58
www.acrivon.com